RBC Capital analyst Brian Abrahams maintained a Hold rating on Prothena (PRTA – Research Report) on January 13 and set a price target of $56.00. The company’s shares closed last Friday at $56.90.
Abrahams covers the Healthcare sector, focusing on stocks such as Regeneron, Biogen, and Incyte. According to TipRanks, Abrahams has an average return of 7.7% and a 49.30% success rate on recommended stocks.
Prothena has an analyst consensus of Strong Buy, with a price target consensus of $83.14.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $66.47 and a one-year low of $21.06. Currently, Prothena has an average volume of 607.5K.
Based on the recent corporate insider activity of 82 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PRTA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Prothena Corp. Plc is a late-stage clinical biotechnology company, which research, development and commercialization of therapies in the neuroscience and orphan categories. Its antibody-based product candidates target a potential indications including amyloidosis and Parkinson’s disease. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Read More on PRTA: